KR20190132335A - Composition comprising corni fructus extracts for preventing or treating benign prostatic hypertrophy - Google Patents

Abstract

The present invention relates to a composition for preventing or treating benign prostatic hyperplasia, which blocks an expression of 5α-reductase and androgen receptor by including a cornus officinalis extract as an active ingredient. The composition blocks an expression of 5α-reductase and androgen receptor to prevent or treat benign prostatic hyperplasia. In addition, a functional tea and other functional foods including the composition for preventing or treating benign prostatic hyperplasia, including the cornus officinalis extract as an active ingredient, can be produced, thereby providing a food having high preference while preventing or treating benign prostatic hyperplasia.

Description

Composition for preventing or treating benign prostatic hyperplasia comprising cornus extract as an active ingredient {COMPOSITION COMPRISING CORNI FRUCTUS EXTRACTS FOR PREVENTING OR TREATING BENIGN PROSTATIC HYPERTROPHY}

The present invention relates to a benign prostatic hypertrophy bread or a composition for treatment comprising a cornus extract as an active ingredient. More specifically, the present invention relates to a composition capable of preventing or treating benign prostatic hypertrophy by blocking the expression of 5α-reductase and androgen receptor.

Benign prostatic hypertrophy (BPH) is a common symptom in old age, and benign prostatic hypertrophy is characterized by malignant enlargement of the prostate due to uncontrolled proliferation of smooth muscle and epithelial cells located in the urethral metastasis zone of the prostate surrounding the urethra. The pathogenesis of benign prostatic hyperplasia is not yet clear, but changes in androgen associated with aging are considered to be one of the important factors essential for the development of prostate growth.

Dihydrotestosterone (DHT) is the most important enzyme. Dihydrotestosterone is converted from testosterone to the prostate by an enzyme involved in steroid metabolism, 5α-reductase, and interacts with the androgen receptor (AR) with a higher affinity than testosterone.

Therefore, excessive production of dihydrotestosterone with reduced testosterone concentrations leads to proliferation of epithelial and stromal cells of the prostate, stimulating the development of benign prostatic hyperplasia.

In addition, the serum concentrations of prostate specific antigen (PSA), which is widely used for the diagnosis of benign prostatic hyperplasia, are of similar age in patients with benign prostatic hyperplasia because PSA production is facilitated by binding dihydrotestosterone to the androgen receptor. It was found to increase compared to normal.

Prostatectomy for benign prostatic hyperplasia is currently the most common surgical method in the world, but it can cause many complications such as bleeding, urethral stenosis and incontinence and may be limited for older people.

As an alternative to surgical treatment, it is largely divided into (α) 1 -adrenoreceptor antagonists (α-blockers) and 5α-reductase inhibitors (5ARI) for the treatment of benign prostatic hyperplasia. Various drugs were used.

However, α-blockers cannot directly reduce the size of prostatic hyperplasia and show side effects such as orthostatic hypotension, nasal congestion, helplessness, sexual dysfunction, dizziness and headache. 5ARI also suffers from various side effects on the reproductive organs, including impotence and limb dysfunction and decreased libido.

Therefore, recently, as a more effective and safe treatment strategy for patients with benign prostatic hyperplasia, there has been a great interest in the application of anti-positive prostatic hypertrophy active agents.

(Patent Document 1) KR 10-0769412 B1

An object of the present invention is to provide a composition for the prevention or treatment of benign prostatic hyperplasia comprising cornus extract as an active ingredient.

Another object of the present invention is to provide a composition comprising a cornus extract as an active ingredient that blocks the expression of 5α-reductase and androgen receptor, thereby preventing or treating benign prostatic hypertrophy.

Still another object of the present invention is to provide a functional tea and other functional foods comprising the composition for the prevention or treatment of benign prostatic hyperplasia comprising the cornus extract as an active ingredient, thereby preventing or treating benign prostatic hyperplasia with high palatability. It is to provide food.

In order to achieve the above object, the composition for preventing or treating benign prostatic hyperplasia according to an embodiment of the present invention comprises a cornus Fructus extract as an active ingredient, the cornus extract is 5α-reductase and androgen It can block expression of Androgen receptor.

The cornus extract may be extracted with a solvent selected from the group consisting of water, alcohols having 1 to 6 carbon atoms, and mixtures thereof.

The cornus extract is extracted by inoculating the microorganisms into cornus, fermented cornus milk fermented.

The microorganisms are Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus rhamnosus, Lactobacillus rhamnosus, Lactobacillus plantarum plantarum Lactobacillus helveticus, Lactobacillus fermentum, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus delbruecchi (Lactobacillus relacibacillus, Lactobacillus delbrueckii) Lactobacillus lactocose, such as Lactobacillus reuteri, Lactobacillus buchneri, Lactobacillus gasseri, Lactobacillus johonsonii, Lactobacillus kefir, Lactobacillus kefir, etc. lactis, Lactococos Planta Room (Lactoc) occus plantarum, Lactococcus raffinolactis, Enterococcus faecalis, Enterococcus faecium, Streptococcus thermophilus, Leuconostoktis Lactic acid Coxsai and Bifidobacterium animals, Bifidobacterium bifidum, Bifidobacterium breb, such as Leuconostoc lactis, Leuconostoc mesenteroides, etc. breve, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium pseudolongum, Bifidobacterium themophilum, Bifidobacterium themophilum Bifidobacteria, such as Bifidobacterium adolescentis, and the like, more preferably lactobacil Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium breve, Bifidobacterium breve and Lactobacillus acido (Lactobacillus acidophilus) is one or more selected from the group consisting of.

The composition for preventing or treating benign prostatic hyperplasia may further include a silk-tree extract.

The composition for preventing or treating benign prostatic hyperplasia may further include an extract of Kochia scoparia (L.) Schrad.

The pharmaceutical composition according to another embodiment of the present invention may include a composition for the prevention or treatment of benign prostatic hyperplasia comprising the cornus extract as an active ingredient.

A food composition according to another embodiment of the present invention may include a composition for preventing or treating benign prostatic hyperplasia, which comprises a cornus extract as an active ingredient.

Tea (茶) according to another embodiment of the present invention may include a composition for preventing or treating benign prostatic hyperplasia comprising a cornus extract as an active ingredient.

Hereinafter, the present invention will be described in more detail.

The composition for preventing or treating benign prostatic hyperplasia according to an embodiment of the present invention may include cornus extract as an active ingredient.

Recently, due to aging, there is a growing interest in using natural products to overcome the side effects of rapidly increasing benign prostatic hypertrophy treatment. The incidence and progression of benign prostatic hyperplasia not only alters the activity of hormones involved in the regulation of prostate function, but also plays an important role in inflammation and oxidative stress.

Thus, natural products with anti-inflammatory and antioxidant properties may be useful for the treatment of benign prostatic hyperplasia. The present invention took advantage of the effect of Corni Fructus, which is known to have high anti-inflammatory and antioxidant activity. Natural products have been found that are likely to treat benign prostatic hyperplasia from traditional medicinal resources, and the present invention intends to use cornus extract.

Corni Fructus has long been considered to be beneficial to a wide range of medical treatments as well as to improve tonicity and blood circulation. Recent studies have found that Cornus extract has various pharmacological actions such as anti-inflammatory, antioxidant, immune regulation, anti-tumor, diabetes, hyperglycemia, liver protection and anti sepsis.

Cornus extract significantly reduced prostate hypertrophy and histopathological changes in testosterone propionate (TP) -induced positive prostatic hyperplasia mice associated with inhibition of expression of 5α-reductase in prostate tissue and concentration of enzymes in serum. Confirmed.

Cornus extract also significantly blocked the testosterone and dihydrotestosterone levels in the serum of benign prostatic hypertrophy rats, and also inhibited the expression of androgen receptors and PSA production. These results indicate that cornus extract can effectively prevent the progression of benign prostatic hyperplasia and can be used as a treatment for benign prostatic hyperplasia.

Although the pathogenesis of benign prostatic hyperplasia is not well known, 5α-reductase is recognized as a major target for the control of benign prostatic hyperplasia because it is the most important enzyme for dehydrotestosterone biosynthesis from testosterone. Of the three 5α-reductases, types I and II are the most clinically important.

Type 2, located in the prostate nuclear membrane of epilepsy and epithelium, has been reported to be more involved in the production of dihydrotestosterone associated with benign prostatic hyperplasia. Testosterone and dihydrotestosterone play an important role in the development of male reproductive organs, but dihydrotestosterone has a higher affinity for androgen receptors than testosterone. The high affinity of dihydrotestosterone for the androgen receptor can strongly stimulate the transcriptional activity of the androgen dependent growth factor required to promote proliferation of prostate epithelial and stromal cells rather than testosterone.

This process requires the recruitment of coactivators of specific androgen receptors to bind to the DNA sequences of androgen response elements (AREs), which are caused by the transfer of androgen receptors to the nucleus.

Ultimately, overproduction of dihydrotestosterone with aging leads to the development and exacerbation of benign prostatic hyperplasia. Cornus extract significantly lowered the levels of 5α-reductase type 2, serum testosterone and dihydrotestosterone in benign prostatic hypertrophy rats.

Consistent with a decrease in serum 5α-reductase type 2 levels, protein expression of the enzyme in prostate tissue was decreased in rats treated with cornus extract and decreased expression of androgen receptor co-activators including androgen receptors, ARA70 and SRC1. Related to.

This phenomenon can also be observed in the group of finasterides, which are selective inhibitors of 5α-reductase type 2 isoenzymes. The present results thus suggest that the blocking effect of Cornus extract on increased prostate weight and histological changes in animals caused by benign prostatic hyperplasia is probably due to decreased 5α-reductase and androgen receptor activity.

PSA is one of the representative androgen-responsive genes expressed in the prostate. Small amounts of PSA are usually detected in the blood of healthy men, but PSA levels are widely used as an indicator of prostate cancer progression.

However, in patients with benign prostatic hyperplasia with high dehydrotestosterone activity, dihydrotestosterone binds to the androgen receptor and interacts with ARE at the promoter site of PSA to enhance the transcriptional activity of PSA. Therefore, PSA levels increase in the serum of patients with benign prostatic hyperplasia, as well as in patients with prostate cancer, so decreasing PSA levels may have a therapeutic effect on benign prostatic hyperplasia. The present invention also examined whether PSA levels could be reduced by treatment with cornus extract in benign prostatic hypertrophy-inducing animals.

As a result, it was confirmed that the amount of PSA in the serum and the expression in the prostate tissue of benign prostatic hypertrophy rats were significantly suppressed in the rats treated with Cornus extract. These results indicate that cornus extract attenuated the androgen signaling system in prostate cells. This may be due to the reduction and production of PSA expression by treatment with Cornus extract.

The cornus extract may be extracted with a solvent selected from the group consisting of water, alcohols having 1 to 6 carbon atoms, and mixtures thereof. The 'cornus extract' refers to an extract obtained by extracting cornus milk.

The hawthorn extract may be eluted with a polar solvent such as C ₁ to C ₆ alcohols such as water, ethanol, methanol, or a mixed solvent having a mixing ratio of 1: 0.1 to 1:10 of alcohol and water. More specifically, water may be used as the extraction solvent. At this time, the extraction temperature may be an extract extracted at 10 ℃ to 100 ℃, preferably room temperature.

The extraction solvent may be used 2 to 50 times by weight of the sample, preferably 2 to 20 times. For extraction, the sample may be left for 1 to 72 hours for leaching in the extraction solvent, in particular 1 to 24 hours.

The filtered extract may be a result obtained by concentrating under reduced pressure with a vacuum rotary concentrator, but is not limited thereto, as long as it is a cornus extract that may exhibit the prophylactic or therapeutic effect of benign prostatic hyperplasia of the present invention, and the extract, a dilution or concentrate of the extract, It includes both a dried product obtained by drying the extract, or a modifier or purified product thereof.

The cornus is the fruit of Cornus officinalis, cornus extract is excellent in preventing or treating benign prostatic hyperplasia.

Meanwhile, the cornus extract may be fermented after preparing the extract using cornus oil. When fermenting the cornus extract has a low cytotoxicity can be used stably at a relatively high concentration.

The microorganisms used for the fermentation include Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus rhamnosus, Lactobacillus rhamnosus and Lactobacillus plantarum. Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus fermentum, Lactobacillus paracasei, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus del brui del bruii Lactobacillus kefir, Lactobacillus kefir, Lactobacillus keuter, Lactobacillus buchneri, Lactobacillus gasseri, Lactobacillus johonsonii, Lactobacillus kefir Lactococcus lactis, lactoco Lactococcus plantarum, Lactococcus raffinolactis, Enterococcus faecalis, Enterococcus faecium, Streptococcus thermophilus, Streptococcus thermophilus Lactic acid cocci and Bifidobacterium animals, Bifidobacterium bifidum, Bifidobacterium, such as Leukonostoc lactis, Leuconostoc mesenteroides Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium pseudolongum, Bifidobacterium turmofilum , Bifidobacterium adolescentis, and the like, and may also contain Bifidobacterium adolescentis. Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium, Bifidobacterium breve, Bifidobacterium, and Lactobacillus casei Bacillus adophyllus (Lactobacillus acidophilus) may be one or more selected from the group consisting of.

The composition for preventing or treating benign prostatic hypertrophy may further include a silk-tree extract.

The silk tree is a tree that symbolizes the couple's golden thread, and is also called a sum-of-the-law, a mixed-married water, a wild field water, or an oiled water. For this reason, many trees were planted in the yard as garden trees. Since it was a tree used to make the handle of the silk, there is a place called a silk tree, and the cow eats well.

In addition, the trunk of the tree is bent or slightly laid down. It is 3 ~ 5m high, and large branches are sparse. Small branches have ridges. Arins of winter snow (芽 鱗, a piece of solid scales covering the winter snow) are 2-3 but small enough to be hard to see. The leaves are alternated and the two-folded double leaves. The leaf is curved like a sickle, long oval with the same right and left side, and the edge is flat. The leaves are 6-15mm long and 2.5-4.0mm wide, with hairs on both sides or on the veins on the back.

The flower is light pink and blooms in June or July, and hangs in the shape of 15 to 20 at the end of a small branch. Calyx and corolla are shallowly divided into 5 and turn green. Surgery is about 25, long out and the upper part is red. The flower appears red because of the color of the stamens. Fruits ripen from late September to early October, flat pods, about 15 cm long, containing 5 or 6 seeds. The peculiarity is that the nerve sheath or mimosa are attached to the external stimulus, but the algae are folded after the sun goes down.

When the mixed extract of the Albizia julibrissin is used in the Cornus extract, the effect of blocking the expression of 5α-reductase and androgen receptor is increased according to the synergistic effect of the mixed use. Therefore, a smaller amount may have an excellent effect in preventing or treating benign prostatic hyperplasia.

The composition for preventing or treating benign prostatic hyperplasia may further include an extract of Kochia scoparia (L.) Schrad.

The dapsali grows in the field, a year old, reaches 1m in height, grows straight, and branches are many. Leaves are regenerated, lanceolate, narrow at both ends, flat at the edges, and have 3 veins. Flowers hang on axillary leaves in July-August. Fruits are poultry, discoid, with a pistil at the end and one seed in it.

The Dapsari extract is extracted from Jeonju collected by drying the Jeonju in the autumn fruit ripening season.

The composition for preventing or treating benign prostatic hyperplasia may further include an extract of Achyranthes japonica (Miq.) Nakai.

The knee is a perennial herb growing in the field of 50-100cm in height and the main stem is square and many branches are divided. The leaves are viviparous, oval or obovate, narrow at both ends, and have some hairs. Flowers run as aquatic inflorescences at the end of axils and branches from August to September. Fruits are enclosed in calyx with pores and seeds are yellowish green.

The iron knee extract is extracted from the iron knee root in winter, using the sun-dried, dried iron knee root.

In the case of using a mixture of the extract of Albizia julibrissin, Dapsari extract, and horsetail knee extract, the synergistic action of each extract is used to block the expression of 5α-reductase and androgen receptor. The effect is raised. Therefore, a smaller amount may have an excellent effect in preventing or treating benign prostatic hyperplasia.

Preferably, the composition for preventing or treating benign prostatic hyperplasia may include 1 to 15 parts by weight of the extract of Albizia julibrissin, 20 to 30 parts by weight of Dipsari extract, and 10 to 30 parts by weight of cow knee extract based on 100 parts by weight of the cornus extract. According to the above range, the synergistic effect of the critical significance is expressed as a synergy effect by the interaction of each extract, and when outside the above range, the synergistic effect is rapidly lowered or almost disappears.

Also more preferably, the composition for preventing or treating benign prostatic hyperplasia may include 5 to 10 parts by weight of Albizia julibrissin, 20 to 25 parts by weight of Dipsari extract, and 15 to 20 parts by weight of cow knee extract, based on 100 parts by weight of the cornus extract. have.

According to the above range, the effect of blocking the expression of 5α-reductase and androgen receptor is enhanced by a higher synergistic effect by the mixing action of each extract, thereby preventing or treating benign prostatic hyperplasia. It can exhibit excellent effects.

Also preferably, the composition for anti-inflammatory and antioxidant activity may further include an extract of Yellow melilot, Pachysandra terminalis and Hosta longipes extract. When the extract is further included, the fragrance of the upper leaf is neutralized and the flavor is improved by mixing with other extracts can be provided in a more palatable food composition.

Yellow melilot is also called vegetation (Melitous). It is native to northern China. It grows in lowland grasses. Its height is 60-90cm and its branches are split and scent when dried. Hair is young but disappears later. The leaf is shifted and is a double leaf of three small leaves. Small leaves are long oval or inverted basal with fine teeth on edge. Flowers bloom in July or August, yellow, dense with gunshot shoots at the ends of branches or leaf axes. Calyx has fine hairs. Fruits are egg-shaped, hairless and ripen black. Medicinal herbs are used for fever, eye drops and nephritis. Smaller and whiter flowers are called M. alba. All of them were grown as grassy resources and grow wild.

Pachysandra terminalis grows in the shade of a tree, with its main stems sideways, with its end straight and green, with fine hairs at first, but gradually disappearing. It grows to around 30cm in height. The leaves are alternated, but they are gathered on the upper part and run like an upside down egg with the teeth on the upper part. Fine hairs on the leaf surface veins, narrowed to form petioles. Flowers bloom in April or May and are white and hang on water inflorescences. The female flower runs a little at the bottom of the ear and the male flower runs a lot at the top. Calyxes are divided into four, without petals. The surgery is 3 to 5 and the style is divided into two and flipped. Fruits are nucleus, oval, hairless on the outside. It is distributed in Korea, Japan, Sakhalin Island, and China.

Bibichu (Hosta longipes) grows well in mountain streams or in humid places and is 30 to 40 cm in height. The leaves all sprout from the roots and grow at an angle. The leaves are elliptical, pointed at the end, and have 8 or 9 veins. The flowers are light purple, bloomed in July or August, slanted to one side, running in a gunshot, and the stalk is 30-40 cm long. A bract is thin membranous, purplish white, almost the length of a petiole. The corolla is split into six ends, and the forked piece is flipped back slightly. Six stamens and one pistil come out of the flower for a long time. Fruits are long oval, with capsules. Seeds are black with wings at the edges. Edible light edible planted for ornamental purposes. Wild species are distributed in Korea, Japan and China. Bibichu is a horticultural species developed in various varieties and is popular as a garden plant in foreign countries.

Preferably the composition for the prevention or treatment of benign prostatic hyperplasia may be that containing 1 to 3 parts by weight of electric sarcophagus extract, 5 to 15 parts by weight of guardian herb extract and 5 to 15 parts by weight of nabechu extract based on 100 parts by weight of the cornus extract. have.

According to the above range, the flavor of the cornus extract is greatly improved, thereby providing a functional food composition with excellent palatability, preventing or treating benign prostatic hyperplasia, and particularly having high palatability and having a very advantageous advantage in wide spread.

More preferably, the composition for preventing or treating benign prostatic hyperplasia includes 1 to 15 parts by weight of the extract of Albizia julibrissin, 20 to 30 parts by weight of Dipsari extract, and 10 to 30 parts by weight of cow knee extract, based on 100 parts by weight of the cornus extract. Pear extract may be 1 to 3 parts by weight, 5 to 15 parts by weight of guardian herb extract, 5 to 15 parts by weight of jade extract.

According to the above range, the anti-inflammatory activity and antioxidant activity are greatly increased due to the synergistic effect by the mixing action of each extract, and the flavor is excellent according to each combination, so that it can be provided as a food composition having high functionality and palatability. .

The pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier. Compositions comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations. When formulated, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used. Solid form preparations for oral administration may include tablet pills, powders, granules, capsules, and the like, which may include at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose), gelatin and the like can be mixed. In addition to the simple excipients, lubricants such as magnesium stearate, talc and the like can also be used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

In addition, the pharmaceutical composition of the present invention is from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories It may have any one formulation selected.

Cornus extract of the present invention has been used for food and medicinal use since ancient times, and there is no particular restriction on its dosage, body absorption, weight, age of patients, sex, health condition, diet, time of administration, administration method, excretion rate And the severity of the disease. In general, the cornus extract may be administered about 10 to 1000 mg per kg of body weight, and more preferably about 50 to 500 mg per kg of body weight. The pharmaceutical composition comprising the cornus extract of the present invention as an active ingredient is prepared in consideration of the effective amount range, and the unit dosage form formulated in this way is required by the judgment of experts and the individual to monitor or observe the administration of the drug, if necessary. Depending on the specific dosage regimen, it may be administered several times at regular time intervals.

The present invention also provides an active quasi-drug composition for the prevention or treatment of benign prostatic hyperplasia comprising cornus extract as an active ingredient. The preparation and composition of the cornus extract is as described above. More specifically, the cornus extract of the present invention may be added to the quasi-drug composition for the purpose of preventing or treating a benign prostatic hyperplasia.

In the present invention, the quasi-drug is a fiber, a rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or animal, has a weak action on the human body or does not directly act on the human body, Non-mechanical and similar or articles of manufacture which are used for disinfection, insecticide and similar purposes for the purpose of preventing infections, for the purpose of diagnosing, treating, reducing, treating or preventing human or animal diseases. It means an article other than an instrument, a machine or a device, and a product which is not an instrument, a machine or a device, which is used for the purpose of pharmacological influence on the structure and function of a person or animal.

When the cornus extract of the present invention is used as a quasi-drug additive, the cornus extract may be added as it is, or may be used together with other quasi-drugs or quasi-drug components, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the intended use.

The quasi-drug composition of the present invention may be, but is not limited to, a disinfectant cleaner, shower foam, gagrin, wet wipes, detergent soap, hand wash, humidifier filler, mask, ointment or filter filler.

The present invention also provides a health functional food composition for preventing or treating benign prostatic hyperplasia comprising cornus extract as an active ingredient. The preparation and composition of the cornus extract is as described above. More specifically, the cornus extract of the present invention may be added to the dietary supplement composition for the purpose of preventing or treating the activity of benign prostatic hyperplasia.

When the cornus extract of the present invention is used as a dietary supplement, the cornus extract may be added as it is, or may be used together with other dietary supplements or dietary supplements, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the intended use.

There is no particular limitation on the type of dietary supplement of the present invention. Examples of health functional foods to which the extract mixture can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, various soups, drinks, tea , Drinks, alcoholic beverages and vitamin complexes, and the like, may include all of the health functional foods in the conventional sense, and may include foods used as feed for animals. In addition to the above, the nutraceutical composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin , Alcohols, carbonating agents used in carbonated drinks, and the like. Others may contain pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks.

In the present invention, the term 'administration' means introducing the pharmaceutical composition of the present invention to a suspected benign prostatic hypertrophy by any suitable method, and the route of administration is administered through various routes of oral or parenteral as long as the target tissue can be reached. Can be.

The method of treatment of the present invention may comprise administering a pharmaceutical composition comprising a cornus extract as an active ingredient in a pharmaceutically effective amount. Suitable total daily doses may be determined by the treating physician within the scope of good medical judgment and may be administered once or in divided doses. However, for the purposes of the present invention, the specific therapeutically effective amount for a particular patient is determined by the specific composition, including the type and extent of the reaction to be achieved, whether or not other agents are used in some cases, the age, weight, general health of the patient, It is desirable to apply differently depending on various factors and similar factors well known in the medical field, including sex and diet, time of administration, route of administration and rate of composition, duration of treatment, drugs used with or co-specific with the specific composition.

According to the composition for the prevention or treatment of benign prostatic hyperplasia of the present invention, by including the cornus extract as an active ingredient, by blocking the expression of 5α-reductase and androgen receptor (Androgen receptor), it is possible to prevent or treat benign prostatic hyperplasia have.

In addition, it is possible to manufacture a functional tea, and other functional foods comprising a composition for preventing or treating benign prostatic hyperplasia comprising the cornus extract as an active ingredient to provide a high-quality food with the prevention or treatment of benign prostatic hyperplasia. have.

1 relates to the effect of the cornus extract on the weight of the prostate gland in testosterone propionate-induced benign prostatic hypertrophy rats, and relates to the change in the total weight of the prostate gland.
Figure 2 relates to the administration effect of cornus extract on the weight of the prostate gland in testosterone propionate-induced benign prostatic hypertrophy rats, and relates to the change in the proportion of prostate weight.
Figure 3 relates to the administration effect of cornus extract on histological changes in the prostate tissue of testosterone propionate induced benign prostatic hyperplasia rats.
Figure 4 relates to the administration effect of Cornus extract on testosterone and DHT in the serum of testosterone propionate-induced benign prostatic hypertrophy rats, and relates to the serum concentration of testosterone.
FIG. 5 relates to the administration effect of Cornus extract on testosterone and DHT in serum of testosterone propionate induced benign prostatic hypertrophy rats, and relates to the serum concentration of DHT.
FIG. 6 relates to the administration effect of Cornus extract on 5α-reductase type 2 in testosterone propionate-induced benign prostatic hypertrophy rats, and relates to serum concentration of 5α-reductase type 2. FIG.
Figure 7 relates to the administration effect of cornus extract on 5α-reductase type 2 of testosterone propionate-induced benign prostatic hypertrophy rats, a photograph of prostate tissue immunostained with anti-5α-reductase type 2.
Figure 8 relates to the effect of the cornus extract on 5α-reductase type 2 of testosterone propionate-induced benign prostatic hypertrophy mice, the expression level of 5α-reductase type 2 in the prostate tissue determined by Weston blot It is about.
Figure 9 relates to the administration effect of cornus extract on androgen receptor expression in testosterone propionate-induced benign prostatic hypertrophy rats, which is a photograph of prostate tissue immunostained with anti-androgen receptor.
Figure 10 relates to the administration effect of cornus extract on androgen receptor expression in testosterone propionate-induced benign prostatic hypertrophy rats, and relates to the expression level of androgen receptor and androgen receptor co-activator.
FIG. 11 relates to the administration effect of Cornus extract on PSA in testosterone propionate induced benign prostatic hypertrophy rats, and relates to the serum concentration of PSA.
Figure 12 relates to the administration effect of Cornus extract on PSA in testosterone propionate induced benign prostatic hyperplasia rats, and relates to the expression level of PSA in prostate tissue determined by Western blot.

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily practice the present invention. As those skilled in the art would realize, the described embodiments may be modified in various different ways, all without departing from the spirit or scope of the present invention.

Preparation Example: Preparation of Cornus Extract

Corni Fructus, a dried fruit provided by the Gurye Cornus Nonghyup Corporation, was harvested in an area of Gurye (Jeollanam-do). Samples were freeze dried for 24 hours in a low temperature drying room adjusted to 15 ° C. and 15% relative humidity to maintain moisture content within 15%. Freeze dried cornus oil was cut into small pieces and then boiled with distilled water for 1 hour. To remove insoluble matters, the extract was filtered with a 0.45 mM filter and the filtrate (Horse-hydrothermal hydrothermal extract, hereinafter referred to as "CF") was lyophilized using a vacuum rotary evaporator (BUCHI, Switzerland) and then used at -20 ° C until use. Kept.

Experimental Example 1: Blocking effect test of expression of 5α-reductase and androgen receptor using cornus extract

1. Experiment Method

animal

Six-week-old male Sprague-Dawley rats (Sprague-Dawley rats, Samtako Bio Korea, Osan, Republic of Korea) having an initial weight of 200-220 g were used. The animals were stored in a room free of pathogens and maintained under standard laboratory conditions (23 ± 2 ° C., 70 ± 5% relative humidity, 12 hour contrast cycle). All animal experiments were conducted in accordance with the Dong-Eui University Animal Experiment Ethics Committee (Confirmation number R2017-004).

Experimental procedure

After 1 week acclimation to the laboratory environment, rats were randomly divided into the following groups (n = 6).

(a) normal control group administered phosphate buffered saline (PBS) with corn oil; (b) a group of benign prostatic hyperplasia administered with PBS with TESTOSTERONE PROPIONATE (TP) (3 mg / kg, Tokyo Chemical Industry Co., Tokyo, Japan); (c) a group administered CF (250, 500 and 700 mg / kg) with TESTOSTERONE PROPIONATE (TP) (3 mg / kg); (d) positive controls administered finasteride (5 mg / kg, Sigma-Aldrich Chemical Co., St Louis, MO, USA) with TESTOSTERONE PROPIONATE (TP) (3 mg / kg); TESTOSTERONE PROPIONATE (TP) -induced benign prostatic hyperplasia was administered testosterone propionate (TESTOSTERONE PROPIONATE, TP) (3 mg / kg) at a dose of 0.1 mL at a 0.1 mL dose for 7 weeks.

At the end of the experiment, animals were anesthetized to collect blood samples from the femoral vein for biochemical analysis. At the same time, prostate and major organs such as lung, heart, spleen, liver and kidney were also recovered and weighed.

The relative prostate weight ratio was calculated as follows:

Relative prostate weight ratio = prostate weight in experimental group / rat prostate weight in control group.

The rest of each prostate was stored at -80 ° C and used for further analysis.

Histopathological examination by hematoxylin and eosin (H & E) staining

After prostate was fixed in 10% buffered formaldehyde solution for 24 hours, tissue samples were paraffin-embedded and cut. Section tissues were stained with H & E (Sigma-Aldrich Chemical Co.) and histological changes were assessed at 200 × magnification using an optical microscope (Carl Zeiss, Oberkochen, Germany).

Immunohistochemical Analysis

Tissue sections were subjected to 5α-reductase type 2 (1:50 dilution, BioRad Laboratories, Inc., Hercules, CA, USA) and androgen receptor (1:50 dilution, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was incubated at 4 ℃. After overnight, the sections were horseradish peroxidase (HRP) -conjugated goat anti-rabbit IgG or HRP-conjugated goat anti-mouse IgG (affinipure Goat anti-mouse). IgG) (1: 500 dilution, Jackson Immunoresearch Lab., West Grove, Pa., USA). 30 minutes at room temperature. Slides were washed with PBS and developed with diaminobenzidine solution in the presence of hydrogen peroxide and visualized by fluorescence microscopy (Carl Zeiss).

Western blot analysis

The prepared prostate tissue was cut into small pieces and homogenized using PROPREP lysis buffer (Intron Biotechnology Inc., Seongnam, South Korea). Tissue extracts were centrifuged at 13,000 rpm for 20 minutes to remove insolubles and the protein concentration of the supernatant was calculated according to the manufacturer's protocol using BioRad Protein Assay (BioRad Laboratories Inc.).

Protein equivalents (30 μg) per sample were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane. The membrane was blocked with TBST (10 mM Tris, 150 mM NaCl and 0.05% Tween-20, pH 7.6) containing 5% skim milk for 1 hour at room temperature, washed with TBST, and then subjected to the appropriate primary androgen receptor (Santa Cruz Biotechnology, Inc.). Androgen receptor related protein 70 (ARA70, Santa Cruz Biotechnology, Inc.), steroid receptor coactivator-1 (SRC-1), 5α-reductase type 2 (Thermo Scientific, Waltham, MA, USA), PSA (Santa Cruz Biotechnology, Inc.) and Actin (actin, Santa Cruz Biotechnology, Inc.) were incubated overnight at 4 ° C.

The membrane was then reacted with the appropriate HRP-conjugated secondary antibody (Amersham Biosciences, Westborough, Mass., USA) for 2 hours at room temperature. Protein bands were detected using enhanced chemiluminescence (ECL) kit (Amersham Biosciences) according to the manufacturer's instructions.

Measurement of biochemical markers

Collected blood samples (5 mL each) were coagulated by holding at room temperature for 30 minutes and then centrifuged at 3000 g at 4 ° C. for 20 minutes to separate serum. Alanine aminotransferase (ALT), Asparta using a biochemistry automatic analyzer (Hitachi High-Technologies, Tokyo, Japan) according to the protocol presented in the assay kit (Asan Pharm, Seoul, Repbulic of Korea) Liver and kidney function was assessed by detecting levels of aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine.

Statistical analysis

All data are expressed as mean ± standard error (SEM). Statistically, Values were analyzed using one-way analysis of variance (ANOVA) using Dunnett's test. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) statistical analysis software (version 19.0, IBM, NY, USA). P values below 0.05 were considered significant.

2. Experimental Results

Effect of Cornus Extract on Prostate Weight in Benign Prostatic Hyperplasia-induced Rats

The effect of CF with increased prostate weight in TESTOSTERONE PROPIONATE (TP) -induced BPH rats is shown in FIGS. 1 and 2. It was confirmed that testosterone propionate (TP) induced BPH successfully by significantly increasing the prostate weight of the benign prostatic hypertrophy group compared to the control group.

However, the CF group showed a significant tendency to decrease the prostate weight in a concentration-dependent manner. The finasteride treatment group used as a positive group also significantly reduced prostate weight compared to the benign prostatic hyperplasia group.

Effect of Cornus Extract on Prostate Histological Changes in Benign Prostatic Hyperplasia-induced Rats

To compare the histological changes of Cornus extract (CF), H & E staining was performed on the prostate tissue and the reassuring effect of prostatic hypertrophy was reconfirmed. As shown in Figs. 4 and 5, pathological changes such as reduction of cytoplasm and lumen and polyp formation by cell proliferation were observed in mice induced with benign prostatic hyperplasia.

However, typical histological patterns of hyperplasia decreased with increasing concentrations in the CF-treated group, and no pathological features were observed in the finasteride-treated group.

Effect of Cornus Extract on the Levels of Testosterone and Dihydrotestosterone in Serum of Benign Prostatic Hypertrophy Rats

As shown in Figures 4 and 5, testosterone and dihydrotestosterone, which are the major causes of benign prostatic hyperplasia in serum, were significantly higher in the benign prostatic hyperplasia group than the control group.

However, compared with the benign prostatic hyperplasia group, the concentration was significantly decreased in the CF group, and the finasteride group was significantly decreased in the control group.

Effect of Cornus Extract on Concentration and Expression of 5α-Reductase Type 2 in Rat Serum and Prostate Tissue

As shown in FIG. 6, the concentration of serum 5α-reductase type 2 was significantly increased in the benign prostatic hypertrophy-induced group compared with the control group. In the CF-treated group, however, the concentration gradually decreased as the CF-treated concentration increased, and the finasteride-treated group was also significantly lower in the benign prostatic hypertrophy-induced group.

In microscopic examination of prostate tissue, expression of 5α-reductase type 2 was increased in the benign prostatic hypertrophy-induced group but suppressed in the CF and finasteride treated groups (FIG. 7).

In addition, the expression level of 5α-reductase type 2 protein in prostate tissues was compared to investigate whether the effect of CF is related to the expression change of 5α-reductase type 2 protein.

As shown in the immunobulototing results shown in Figure 4C, the levels of 5α-reductase type 2 in prostate tissue induced by benign prostatic hyperplasia were significantly reduced by finasteride and CF treatment.

Effect of Cornus Extract on Expression of Androgen Receptor and Co-Activators of Androgen Receptor in Prostate Tissue

Prostate immunostaining results showed that the expression of androgen receptors was increased in TESTOSTERONE PROPIONATE (TP) -induced benign prostatic hyperplasia, but the CF-treated group, like the finasteride-treated group, was TESTOSTERONE. PROPIONATE, TP) significantly reduced the increased expression of the androgen receptor compared to the administration group (Fig. 9).

In Western blot analysis performed to confirm the results of immunostaining at the protein level, the expression of androgen receptor protein was enhanced in the benign prostatic hyperplasia group. However, increased androgen receptor expression was markedly inhibited by CF treatment, and finasteride treatment also reduced androgen receptor expression (FIG. 10).

In addition, protein levels induced by co-activators of androgen receptors such as ARA70 and SRC1 in the benign prostatic hyperplasia group were down regulated by CF and finasteride treatment (FIG. 10).

Effect of Cornus Extract on the Level and Expression of PSA

The effects of CF treatment at the PSA level were further investigated, and as shown in FIG. 11, it was confirmed that the amount of PSA in serum was significantly increased by TESTOSTERONE PROPIONATE (TP) treatment as shown in the immunohistochemistry results. did.

In contrast, CF and finasteride treatment significantly lowered the amount of PSA in the serum compared to the benign prostatic hyperplasia group. This trend was similarly observed for PSA protein expression in prostate tissue (Figure 12).

Toxicity Evaluation of Cornus Extracts in Benign Prostatic Hypertrophy Rats

To assess the toxicity of CF, the weight of major organs and serum hormone levels were examined.

Groups Weight of major organs (g) Lung Heart Spleen Liver Kidney Control 1.52 ± 0.18 1.22 ± 0.11 0.66 ± 0.03 10.38 ± 1.14 2.51 ± 0.35 Benign prostatic hyperplasia 1.41 ± 0.17 1.20 ± 0.16 0.60 ± 0.06 9.37 ± 1.57 2.83 ± 0.45 CF-250 1.48 ± 0.11 1.23 ± 0.08 0.69 ± 0.11 9.65 ± 1.24 3.08 ± 0.37 CF-500 1.52 ± 0.19 1.23 ± 0.16 0.70 ± 0.10 9.11 ± 3.46 3.06 ± 0.38 CF-700 1.39 ± 0.18 1.20 ± 0.13 0.69 ± 0.04 9.42 ± 1.80 2.75 ± 0.36 Panisteride 1.50 ± 0.18 1.17 ± 0.08 0.68 ± 0.08 10.73 ± 1.27 3.00 ± 0.34

(Values are mean ± standard deviation of 6 weeks. Control group was corn oil infused and PBS-treated rats; benign prostatic hyperplasia was testosterone propionate (3 mg / kg) and PBS treated rats; CF-250 was testosterone pro) Cypionate (3 mg / kg) and CF (250 mg / kg) treated rats; CF-500 treated with testosterone propionate (3 mg / kg) and CF (500 mg / kg) treated rat; CF-700 was tested with testosterone propionate ( 3 mg / kg) and CF (700 mg / kg) treated rats; finasteride was treated with testosterone propionate (3 mg / kg) and finasteride (10 mg / kg) treated rats).

As shown in Table 1, the relative weight of important organs including lung, heart, spleen, liver and kidney of benign prostatic hypertrophy-induced rats, CF-treated rats, and finasteride-treated rats was not significantly different from the normal control group.

Groups ALT (U / L) AST (U / L) BUN (mg / dL) Creatinine
(mg / dL) Control 41.5 ± 6.8 159.3 ± 47.8 18.9 ± 2.1 0.51 ± 0.1 Benign prostatic hyperplasia 45.4 ± 3.8 154.7 ± 31.7 21.8 ± 3.2 0.52 ± 0.1 CF-250 39.7 ± 6.9 146.8 ± 33.9 20.7 ± 3.3 0.48 ± 0.1 CF-500 39.7 ± 5.8 144.7 ± 27.6 21.2 ± 1.8 0.49 ± 0.2 CF-700 41.8 ± 8.6 153.8 ± 18.5 22.5 ± 4.3 0.48 ± 0.1 Finasteride 43.7 ± 15.5 148.3 ± 55.9 21.5 ± 3.3 0.51 ± 0.2

(Values are mean ± standard deviation of 6 weeks. Control group was corn oil infused and PBS-treated rats; benign prostatic hyperplasia was testosterone propionate (3 mg / kg) and PBS treated rats; CF-250 was testosterone pro) Cypionate (3 mg / kg) and CF (250 mg / kg) treated rats; CF-500 treated with testosterone propionate (3 mg / kg) and CF (500 mg / kg) treated rat; CF-700 was tested with testosterone propionate ( 3 mg / kg) and CF (700 mg / kg) treated rats; finasteride was treated with testosterone propionate (3 mg / kg) and finasteride (10 mg / kg) treated rats).

In this experiment we compared the weights of major organs for toxicity tests related to the efficacy of Cornus extract on benign prostatic hyperplasia.

There was no significant change in lung, heart, spleen, liver and kidney weights in the control, finasteride and cornus extract groups. In addition, serum concentrations of AST, AST, BUN and creatinine in rats treated with Cornus extract did not differ significantly from the control group. Although further studies on chronic and genotoxicity are needed to support the safety of Cornus extract, Cornus extract currently has no significant toxic effects on liver and kidney.

In conclusion, the results of the above experiments indicate that cornus extract has a protective effect on rat testosterone propionate-induced positive prostatic hyperplasia, as evidenced by its ability to inhibit prostate growth and tissue damage. This effect means that Cornus extract can effectively reduce the development and progression of benign prostatic hyperplasia because the serum dihydrotestosterone and PSA levels have been reduced with inhibition of at least 5α-reducing enzyme and androgen receptor expression.

Preparation Example 2: Preparation of Mixed Extract

1. Preparation of Silk Tree Extract (SF)

The silk tree is washed, dried and crushed. The milled mixture was mixed with purified water and maintained at 98-100 ° C. for 2 hours, cooled, and filtered through Whatman filter paper to obtain the filtrate.

2. Preparation of Other Plant Extracts

Dapsari extract (KF), horsetail knee extract (AF), horseradish extract (YF), guardian herb extract (PF) and nabechu extract (HF) were prepared in the same manner as the silk tree extract.

3. Preparation of Mixed Extract

The Cornus extract (CF), silk tree extract (SF), Dapsari extract (KF), iron knee extract (AF), horseradish extract (YF), guardian herb extract (PF) and nabechu extract (HF) Table 3 below To prepare a mixed extract by mixing the same composition.

MX1 MX2 MX3 MX4 MX5 MX6 MX7 MX8 MX9 MX10 MX11 CF 100 100 100 100 100 100 100 100 100 100 100 SF 0.5 One 5 10 15 20 10 10 10 10 10 KF 10 20 23 25 30 40 25 25 25 25 25 AF 5 10 15 20 30 40 20 20 20 20 20 YF - - - - - - 0.5 One 2 3 5 PF - - - - - - One 5 10 15 20 HF - - - - - - One 5 10 15 20

(Unit: parts by weight)

[Experimental Example 2: 5α-reductase and androgen receptor expression blocking effect test of the mixed extract]

1. Experimental Effect of Blocking 5α-reductase and Androgen Receptor Expression

In order to confirm the synergistic effect by the interaction of the use of the mixed extract, the expression activity of 5α-reductase and androgen receptor related to the cornus extract (CF) and benign prostatic hyperplasia confirming the positive or enlarged prostate hypertrophy Comparative evaluation.

In the same manner as the above experiment, in the experimental group to which each mixed extract (MX 1 to MX 6) was administered for 7 weeks, the degree of inhibition of expression of 5α-reductase and androgen receptor was evaluated and compared with the result value of the cornus extract. . The cornus extract and each mixed extract were administered at a dose of 10 mg / kg once daily to reduce the amount of the cornus extract and each mixed extract to 10% of the previous dose so that the effects of the use of each mixed extract were directly revealed.

 In addition, the expression inhibitory effect of the 5α-reductase and androgen receptor of the cornus extract (CF) was fixed as an index of 5 and the results of using the mixed extract were expressed as an index of 1 to 10 compared with this. The higher the number, the better the inhibitory activity and the better the anti-inflammatory and antioxidant activity.

The results are shown in Table 4 below.

MF MX1 MX2 MX3 MX4 MX5 Inhibition of 5α-Reductase Expression 5 6 7 9 9 6 Suppresses Androgen Receptor Expression 5 5 6 9 9 5

(Unit: exponent)

Referring to Table 4 it can be seen that the synergistic effect of the use in the mixed extract. In particular, it can be seen that the effect of inhibiting the expression of 5α-reductase and androgen receptor by MX 2 to MX 5 is greatly increased.

Therefore, it can be seen that the synergistic effect of the mixed extract of MX 2 to MX 5 ranges from the simple combination to the synergistic effect of the respective extracts.

Accordingly, it can be seen that when the mixed extract is used, an excellent prophylactic or therapeutic effect can be obtained with respect to benign prostatic hyperplasia in a smaller amount. Therefore, since it can produce a prophylactic or therapeutic effect against benign prostatic hyperplasia at a relatively low concentration, it is possible to manufacture a product comprising a composition for the prevention or treatment of benign prostatic hyperplasia that can be taken for a long time with less side effects.

2. Sensory evaluation

The functionalities of the flavor and taste of each combination were evaluated so that the composition comprising the Cornus extract (CF) and each mixed extract could be provided as a functional food composition.

Therefore, Cornus extract (CF) and mixed extract MX 4, MX 7 to MX 11 each was prepared as a tea beverage, and sensory evaluation was performed for 20 adult men and women. Sensory evaluation was evaluated by the index of 1 to 10 according to the palatability based on the flavor and taste, divided into the average index and the results are shown in Table 5.

On the other hand, the higher the number is, the higher the palatability is.

CF MX4 MX7 MX8 MX9 MX10 MX11 incense 1.5 2 3 7 9 7 5 flavor One One 4 6 8 8 4 Palatability One One 3.5 6.5 8.5 8 4.5

(Unit: exponent)

Referring to Table 5, the cornus extract has a strong bitter taste, a strong astringent taste, low evaluation of the flavor, taste and preference for the cornus extract itself. In addition, MX4, which has been added to the cornus extract, silkworm extract, dapsali extract, and iron knee extract, the positive prostatic hyperplasia improved by mixing the extract, but the flavor and taste are not improved by mutual combination I can see the fact.

However, in the case of mixed with E. hawthorn extract, patina herb extract and beetle extract in a certain range as shown in Table 5, despite the mixing of the albizia extract, Dapsari extract and knee knee extract, the overall flavor and taste is improved I can see the fact.

In particular, referring to MX 8 to MX 10, even if the silk tree extract, dapsali extract, and iron knee extract are mixed in a certain range, the bitter and sloppy taste is removed when the honeybee extract, patissier herb extract and beetle extract are mixed in a certain range. As you can see, the flavor and taste of tea beverages are greatly enhanced by the combination of each extract.

Therefore, according to the mixed extract of the above range, including the Cornus extract, Albizia julibrissin extract, Dipsari extract, and horsetail extract can greatly increase the effect of preventing or treating benign prostatic hyperplasia, as well as excellent flavor and taste as a whole. It can be widely used as functional food or functional tea with higher preference.

Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements of those skilled in the art using the basic concepts of the present invention defined in the following claims are also provided. It belongs to the scope of rights.

Claims (9)

Contains Cornus Fructus extract as an active ingredient,
The Cornus extract blocks the expression of 5α-reductase and androgen receptor.
A composition for preventing or treating benign prostatic hyperplasia comprising cornus extract as an active ingredient. The method of claim 1,
The cornus extract is extracted with a solvent selected from the group consisting of water, alcohols having 1 to 6 carbon atoms and mixtures thereof
A composition for preventing or treating benign prostatic hyperplasia comprising cornus extract as an active ingredient. The method of claim 1,
The cornus extract is inoculated with microorganisms in cornus, extracted using fermented cornus
A composition for preventing or treating benign prostatic hyperplasia comprising cornus extract as an active ingredient. The method of claim 3,
The microorganisms are Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus rhamnosus, Lactobacillus rhamnosus, Lactobacillus plantarum plantarum Lactobacillus helveticus, Lactobacillus fermentum, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus delbruecchi (Lactobacillus relacibacillus, Lactobacillus delbrueckii) Lactobacillus lactocose, such as Lactobacillus reuteri, Lactobacillus buchneri, Lactobacillus gasseri, Lactobacillus johonsonii, Lactobacillus kefir, Lactobacillus kefir, etc. lactis, Lactococos Planta Room (Lactoc) occus plantarum, Lactococcus raffinolactis, Enterococcus faecalis, Enterococcus faecium, Streptococcus thermophilus, Leuconostoktis Lactic acid Coxsai and Bifidobacterium animals, Bifidobacterium bifidum, Bifidobacterium breb, such as Leuconostoc lactis, Leuconostoc mesenteroides, etc. breve, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium pseudolongum, Bifidobacterium themophilum, Bifidobacterium themophilum Bifidobacteria, such as Bifidobacterium adolescentis, and the like, more preferably lactobacil Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium breve, Bifidobacterium breve and Lactobacillus acido (Lactobacillus acidophilus) one or more selected from the group consisting of
A composition for preventing or treating benign prostatic hyperplasia comprising cornus extract as an active ingredient. The method of claim 1,
The composition for preventing or treating benign prostatic hyperplasia further includes a silk-tree extract.
A composition for preventing or treating benign prostatic hyperplasia comprising cornus extract as an active ingredient. The method of claim 1,
The composition for preventing or treating benign prostatic hyperplasia further comprises a extract of Kochia scoparia (L.) Schrad.
A composition for preventing or treating benign prostatic hyperplasia comprising cornus extract as an active ingredient. Claims 1 to 6 comprising a composition for the prevention or treatment of benign prostatic hyperplasia comprising the cornus extract according to any one of claims as an active ingredient
Pharmaceutical composition. Claims 1 to 6 comprising a composition for the prevention or treatment of benign prostatic hyperplasia comprising the cornus extract according to any one of claims as an active ingredient
Food composition. Claims 1 to 6 comprising a composition for the prevention or treatment of benign prostatic hyperplasia comprising the cornus extract according to any one of claims as an active ingredient
Tea.

Images